Elite Graft Program bundles biotech wound care with Medicare audit cover

Three US healthcare firms unite biologic grafts, revenue cycle management and clawback protection into one coordinated wound care model.

By Disrupts Editorial Team Wed, 21 October 2026 AI level 2 of 5

AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean

White robotic arms precisely handle small clear packages in white trays on a production line within a brightly lit, sterile cleanroom.

Cellution Biologics, CHUM Health and Shoreline Medical Administration have jointly launched the Elite Graft Program, a bundled service that attempts to solve one of advanced wound care's most persistent structural problems: a clinically effective treatment means little if the reimbursement claim fails or is clawed back years later.

The programme combines Cellution's AmchoPlast biologic graft, CHUM Health's end-to-end revenue cycle management, and Shoreline's post-payment audit protection under a single coordinated workflow. Each partner retains a separate agreement with the clinical practice, meaning providers are not locked into a single contract.

The clinical and commercial case

AmchoPlast, listed under billing code Q4316, is positioned as a premium skin substitute sourced from human amniotic tissue. The company says multicenter randomised controlled trials showed the graft achieved 71% complete wound closure against 23% for standard care alone, alongside a 78% reduction in wound area. These figures are company-reported and have not been independently verified by Disrupts.

The revenue cycle piece handled by CHUM Health covers the full administrative chain: eligibility checks, prior authorisation, coding review, denial management, appeals and payment reporting. Shoreline's role begins where most revenue cycle services stop. Its Clawback Protection Guarantee provides legal support through Medicare audit appeals and, if those appeals fail, covers both legal costs and the recouped amount. That last element is notable: it shifts financial tail risk away from the clinical practice and onto the administrative partner.

"Advanced wound care requires more than innovative products," said Dinesh Singh, President and CEO of CHUM Health. "It requires a coordinated strategy that supports providers from treatment through reimbursement."

The convergence read-across

The Elite Graft Programme illustrates a structural shift in how regenerative medicine products reach the market. The traditional model asks a biotech to develop an efficacious product and then rely on the provider to navigate reimbursement independently. That model is under strain. Medicare's post-payment audit regime for skin substitutes has intensified in recent years, creating a deterrent effect that suppresses uptake of clinically valid treatments. Bundling compliance infrastructure directly into the commercial offering is an attempt to remove that deterrent at the point of sale.

This pattern, where a life-sciences company embeds fintech-adjacent services to de-risk the customer relationship, is gaining traction across medical device and biologics markets. Revenue cycle management firms are increasingly positioning themselves as strategic partners to biotech commercialisation, not back-office utilities. For investors tracking the convergence of healthcare services and regenerative medicine, the question is whether bundled models of this kind improve durable adoption rates enough to justify the shared margin arrangement.

The macro backdrop matters here too. US Medicare reimbursement policy for advanced wound care biologics has become a contested regulatory space, with audit activity creating significant recoupment risk for smaller practices. A programme that absorbs that risk could expand the addressable market for AmchoPlast beyond the large health systems that have dedicated compliance teams, reaching the independent wound care clinics and podiatry practices that have historically avoided high-cost biologics precisely because of audit exposure.

Whether the model scales depends on several unresolved questions: the sustainability of Shoreline's guarantee economics at volume, the durability of Q4316 coding coverage under future Medicare policy changes, and whether the three-way partnership can maintain coordination as each organisation pursues its own growth. For now, the Elite Graft Programme is a clear signal that in advanced wound care, commercial viability and clinical adoption are being treated as inseparable engineering problems.